These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9151342)

  • 1. Monoclonal antibody therapy of inflammatory bowel disease.
    van Deventer SJ; Camoglio L
    Pharm World Sci; 1997 Apr; 19(2):55-9. PubMed ID: 9151342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody therapy of inflammatory bowel disease.
    van Deventer SJ; Camoglio L
    Aliment Pharmacol Ther; 1996; 10 Suppl 2():107-11; discussion 112. PubMed ID: 8899109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody].
    Asakura H
    Nihon Rinsho; 2002 Mar; 60(3):531-8. PubMed ID: 11904969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.
    Hibi T; Inoue N; Ogata H; Naganuma M
    J Gastroenterol; 2003 Mar; 38 Suppl 15():36-42. PubMed ID: 12698869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Standards, perspectives and limits of conservative therapy of chronic inflammatory bowel diseases].
    Rogler G; Andus T; Schölmerich J
    Zentralbl Chir; 1998; 123(4):316-24. PubMed ID: 9622888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
    Sartor RB
    Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of inflammatory bowel disease: past, present and future.
    Keyashian K; Annunziata ML; Sakuraba A; Hanauer S
    Expert Rev Clin Immunol; 2012 May; 8(4):303-5. PubMed ID: 22607175
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy of Crohn's disease.
    van Montfrans C; Camoglio L; van Deventer SJ
    Mediators Inflamm; 1998; 7(3):149-52. PubMed ID: 9705600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.
    Hibi T; Iwao Y; Yajima T; Inoue N; Ueno Y; Takaishi H; Watanabe M; Ishii H
    J Gastroenterol; 1995 Nov; 30 Suppl 8():121-3. PubMed ID: 8563872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene transfer approaches for the treatment of inflammatory bowel disease.
    Wirtz S; Neurath MF
    Gene Ther; 2003 May; 10(10):854-60. PubMed ID: 12732871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody 1F10 immunoreactivity in inflammatory bowel disease: a new marker specific only for continuous endothelial cells.
    Lügering N; Stoll R; Holzgreve A; Winde G; Sorg C; Domschke W
    Eur J Gastroenterol Hepatol; 1995 Aug; 7(8):777-81. PubMed ID: 7496869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
    Dejaco C; Gasché C; Reinisch W; Moser G; Novacek G; Tillinger W; Vogelsang H; Gangl A
    Wien Klin Wochenschr; 1998 Sep; 110(16):579-84. PubMed ID: 9782579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic principles for chronic inflammatory bowel disease].
    Binder V; Munkholm P
    Ugeskr Laeger; 2001 Jan; 163(1):16-21. PubMed ID: 11586666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the immunopathology of chronic inflammatory bowel disease.
    Ehrhardt RO
    Semin Gastrointest Dis; 1996 Jul; 7(3):144-50. PubMed ID: 8817766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathogenetic models ulcerative colitis and Crohn disease].
    Feller AC; Löhler J; Reimann J; Merz H
    Verh Dtsch Ges Pathol; 1996; 80():104-8. PubMed ID: 9064992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDP-02 (Millenium).
    Marshall JK
    Curr Opin Investig Drugs; 2001 Apr; 2(4):502-4. PubMed ID: 11566006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biologic therapy of inflammatory bowel disease].
    Baumgart DC; Wiedenmann B; Dignass AU
    Z Gastroenterol; 2003 Oct; 41(10):1017-32. PubMed ID: 14562200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.